Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, UK.
Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, UK.
Adv Drug Deliv Rev. 2017 Nov 1;121:124-132. doi: 10.1016/j.addr.2017.10.011. Epub 2017 Oct 25.
Novel insights into the epigenetic control of chronic liver diseases are now emerging. Recent advances in our understanding of the critical roles of DNA methylation, histone modifications and ncRNA may now be exploited to improve management of fibrosis/cirrhosis and cancer. Furthermore, improved technologies for the detection of epigenetic markers from patients' blood and tissues will vastly improve diagnosis, treatment options and prognostic tracking. The aim of this review is to present recent findings from the field of liver epigenetics and to explore their potential for translation into therapeutics to prevent disease promoting epigenome reprogramming and reverse epigenetic changes.
目前，人们对慢性肝脏疾病的表观遗传学控制有了新的认识。我们对 DNA 甲基化、组蛋白修饰和 ncRNA 的关键作用的理解的最新进展，现在可能被用来改善纤维化/肝硬化和癌症的治疗管理。此外，用于从患者的血液和组织中检测表观遗传标记的改进技术将极大地改善诊断、治疗选择和预后跟踪。本综述的目的是介绍肝脏表观遗传学领域的最新发现，并探讨其在预防促进疾病的表观基因组重编程和逆转表观遗传变化的治疗中的应用潜力。
